Literature DB >> 17106010

Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters.

John E Murphy1, David E Gillespie, Carol V Bateman.   

Abstract

PURPOSE: Seven methods for estimating vancomycin pharmacokinetic parameters were studied to determine which method best predicted measured concentrations for patients at a community teaching hospital.
METHODS: Data from adult patients who were given vancomycin and had at least one steady-state trough concentration measured were retrospectively reviewed. Data analyzed included laboratory test values, concomitant medications, weight, height, sex, age, laboratory cultures, medical procedures performed, vancomycin dose and interval, measured vancomycin concentrations, and time of measurement. Relevant data were used in seven predictor methods that estimate volume of distribution, vancomycin clearance, and elimination rate constant to determine which yielded the best predictions of actual measured concentrations in the patient population.
RESULTS: Data from 189 patients were included in the analyses. The coefficients of determination for the methods ranged from 0.114 to 0.234. Bias ranged from -5.90 to 0.69 mg/L, and precision ranged from 6.05 to 8.08. The Matzke method had the best combination of the least bias and best precision. Predictions were within 2.5 and 5 mg/L of measured concentrations 18.0-43.9% and 43.4-66.1% of the time, respectively. The percentage of predictions within 25% and 50% of measured concentrations ranged from 7.9% to 31.2% and from 18.0% to 48.1%, respectively. Ten (5.3%) patients had trough concentrations exceeding 20 mg/L, and 11 (5.8%) had trough concentrations of < or = 3 mg/L.
CONCLUSION: The seven methods studied for estimating vancomycin pharmacokinetic parameters varied widely in predicting vancomycin trough concentrations compared with measured serum concentrations and were not sufficiently reliable to replace therapeutic monitoring of vancomycin serum concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17106010     DOI: 10.2146/ajhp060047

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  16 in total

1.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

Review 2.  Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics.

Authors:  Patricia Lee; David DiPersio; Rebecca N Jerome; Arthur P Wheeler
Journal:  J Med Libr Assoc       Date:  2007-10

3.  Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Authors:  Anaïs Glatard; Laurent Bourguignon; Roger W Jelliffe; Pascal Maire; Michael N Neely; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

4.  Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.

Authors:  N Maki; A Ohkuchi; Y Tashiro; M R Kim; M Le; T Sakamoto; S Matsubara; Y Hakamata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-06       Impact factor: 3.267

5.  Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.

Authors:  Pieter J Colin; Karel Allegaert; Alison H Thomson; Daan J Touw; Michael Dolton; Matthijs de Hoog; Jason A Roberts; Eyob D Adane; Masato Yamamoto; Dolores Santos-Buelga; Ana Martín-Suarez; Nicolas Simon; Fabio S Taccone; Yoke-Lin Lo; Emilia Barcia; Michel M R F Struys; Douglas J Eleveld
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

6.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Authors:  Natalia Revilla; Ana Martín-Suárez; Marta Paz Pérez; Félix Martín González; María Del Mar Fernández de Gatta
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 7.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 8.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

9.  Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency.

Authors:  Said Abuhasna; Amer H Al Jundi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-10

10.  Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy.

Authors:  Sara L Van Driest; Tracy L McGregor; Digna R Velez Edwards; Ben R Saville; Terrie E Kitchner; Scott J Hebbring; Murray Brilliant; Hayan Jouni; Iftikhar J Kullo; C Buddy Creech; Prince J Kannankeril; Susan I Vear; Kyle B Brothers; Erica A Bowton; Christian M Shaffer; Neelam Patel; Jessica T Delaney; Yuki Bradford; Sarah Wilson; Lana M Olson; Dana C Crawford; Amy L Potts; Richard H Ho; Dan M Roden; Josh C Denny
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.